Heron Therapeutics Q3 Net Revenue Falls 7.8% as Net Loss Narrows

Heron Therapeutics, Inc. posted third-quarter net revenue of $35.3 million, down 7.8% from a year earlier, while its net loss narrowed amid a proposed sale of substantially all its assets. Net revenue fell from $38.2 million in the year-earlier quarter. Heron posted a GAAP net loss of $5 million, or $0.03 per share, compared with a $17.5 million loss, or $0.10 per share, a year earlier. Oncology revenue declined 22.2% to $20.1 million, while acute care revenue rose 22.5% to $15.1 million. Heron ended the quarter with $23.4 million in cash, cash equivalents and short-term investments. Heron and CorMedix Therapeutics announced an agreement for CorMedix to acquire substantially all of Heron's assets. The proposed sale requires approval from Heron stockholders and remains subject to other closing conditions.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.